Physician profile
Heath E Cotter
NPI 1184819971
$3,375.89
in general payments reported to CMS, 2019-2025
32 companies · $817 in 2025
The $817 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2020: $212 · 2021: $427 · 2022: $464 · 2023: $527 · 2024: $748 · 2025: $817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,092.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,091.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $585.23 | 2024-2025 | |
| Abbvie INC. | $316.87 | 2021-2025 | Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals LP | $316.71 | 2019-2024 | Farxiga |
| Lilly USA, LLC | $289.70 | 2019-2024 | Mounjaro, Zepbound, Emgality |
| Kerecis Limited | $262.93 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Glaxosmithkline, LLC. | $210.04 | 2020-2024 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $179.50 | 2019-2025 | |
| Reprise Biomedical, INC. | $164.23 | 2025 | Miro3d |
| Biohaven Pharmaceuticals, INC. | $139.63 | 2020-2021 | |
| Biowound Solutions, INC. | $98.94 | 2024 | Bio-Connekt |
| Bard Peripheral Vascular, INC. | $87.28 | 2023 | Venovo |
| Astellas Pharma US INC | $78.61 | 2022-2024 | Veozah, Myrbetriq |
| Amgen INC. | $74.80 | 2022-2024 | Repatha, Otezla, Prolia |
| E.R. Squibb & Sons, L.L.C. | $72.20 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $58.13 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $55.81 | 2022 | |
| Janssen Pharmaceuticals, INC | $55.38 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $33.91 | 2020-2021 | |
| Eisai INC. | $32.26 | 2020 | |
| Novo Nordisk INC | $31.80 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $31.11 | 2024 | |
| Shockwave Medical, INC | $25.17 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Mylan Specialty L.P. | $24.85 | 2022 | |
| Allergan, INC. | $23.67 | 2020 | |
| Organogenesis INC. | $23.16 | 2024 | |
| Exact Sciences Corporation | $21.35 | 2023 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $16.68 | 2023 | |
| Ucb, INC. | $16.45 | 2019 | |
| Merck Sharp & Dohme LLC | $13.57 | 2022 | |
| Reddress USA, INC. | $13.20 | 2024 | |
| Sobi, INC | $11.61 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heath Cotter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.